Recent developments include the commencement of dosing in the Phase 2 ALSTARS trial for COYA 302 in ALS, FDA acceptance of IND applications for COYA 302 in ALS and FTD, and a $11.1 million financing led by Dr. Reddy's Laboratories to support manufacturing scale-up. Multiple analyst firms have maintained buy recommendations on the company throughout late 2025.

• In December 2025, dosing commenced in the Phase 2 ALSTARS trial of COYA 302 for ALS, following FDA IND acceptance in August 2025 [S1].
• In January 2026, FDA accepted the IND for COYA 302 for frontotemporal dementia, with plans to advance clinical trials [S1].
• A $11.1 million gross proceeds financing was completed in January 2026, with $10 million from Dr. Reddy's Laboratories to accelerate manufacturing scale-up for COYA 302 [S1].
• Positive interim results from an investigator-initiated open-label study of COYA 302 in FTD patients showed safety and cognitive function stability over 22 weeks [S1].
• Multiple analyst firms including D. Boral Capital, Chardan Capital, and BTIG maintained buy recommendations on Coya Therapeutics during late 2025 [N1,N2,N3,N4,N5,N6,N7].

Coya’s lead candidate COYA 302 targets multiple pathways implicated in neurodegenerative diseases, supported by clinical data and ongoing Phase 2 trials. The company’s strategy to use COYA 301 as a backbone for combination therapies could enable expansion into multiple indications. Positive interim clinical results and collaborations with established institutions like Houston Methodist and Dr. Reddy’s Laboratories enhance development and commercialization prospects. Strong liquidity and recent capital raises support continued operations and pipeline advancement. Multiple buy recommendations from analysts indicate market confidence in the company’s approach.

Coya remains a clinical-stage company with no approved products and a history of operating losses, reflecting the inherent risks of drug development. The success of its pipeline depends on clinical trial outcomes, regulatory approvals, and the ability to secure additional funding. Manufacturing and supply chain dependencies on third parties pose risks of delays or increased costs. The company’s financial condition could be adversely affected if it fails to raise capital on acceptable terms. Competition in the immunomodulatory and neurodegenerative disease space is intense, and scientific or clinical setbacks could impact valuation and operations.

Coya’s moat derives from its proprietary focus on regulatory T cell biology, a niche with growing scientific validation including Nobel Prize-winning discoveries. The company’s multi-modality approach—combining biologics, exosomes, and cell therapy—provides diversified therapeutic avenues. Exclusive licensing agreements with Houston Methodist and Dr. Reddy’s Laboratories for key biologics and biosimilars underpin its intellectual property and manufacturing capabilities. The clinical advancement of COYA 302 and its positioning as a "pipeline within a product" reflect a differentiated approach to complex neurodegenerative diseases, potentially creating barriers to entry for competitors.

• Clinical Development Risk: The company’s product candidates are in early to mid-stage clinical trials, and there is uncertainty regarding their safety, efficacy, and regulatory approval.
• Financial Risk: Coya has incurred significant losses and will require additional capital to continue operations and advance its pipeline, with no assurance of successful financing.
• Manufacturing and Supply Risk: Dependence on third-party manufacturers and licensors for biologics and components may cause delays or increased costs affecting development and commercialization.
• Regulatory Risk: The company must obtain regulatory approvals for its product candidates, which involves complex and uncertain processes subject to delays or denials.
• Market and Competitive Risk: Competition from other companies developing immunomodulatory therapies and neurodegenerative disease treatments may impact market opportunities and pricing.

• Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing proprietary therapies to enhance the function of regulatory T cells (Tregs), which are a subpopulation of T-lymphocytes that suppress inflammatory responses [S1].
• Tregs play a key role in maintaining immune homeostasis by regulating autoimmune and inflammatory responses; dysfunctional Tregs are implicated in neurodegenerative, autoimmune, and metabolic diseases [S1].
• The company has expertise in three therapeutic modalities: Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy, using both ex vivo and in vivo approaches [S1].
• Lead asset COYA 302 is a Treg-enhancing biologic combining low dose interleukin-2 (COYA 301) and CTLA4-Ig, designed to provide sustained effects in neurodegenerative disorders by targeting multiple pathways [S1].
• COYA 302 is in a Phase 2 randomized, double-blind, placebo-controlled trial (ALSTARS) for amyotrophic lateral sclerosis (ALS), with dosing commenced in December 2025 and enrollment anticipated to complete in the second half of 2026 [S1].
• The FDA accepted the IND application for COYA 302 for ALS in August 2025 and for frontotemporal dementia (FTD) in January 2026; the company plans clinical trials for FTD [S1].
• An investigator-initiated proof of concept open-label study of COYA 302 in FTD patients showed no serious adverse events, enhanced Treg numbers and function, and cognitive function stability over 22 weeks [S1].
• COYA 303 is an investigational biologic combining COYA 301 and a GLP-1 receptor agonist, targeting inflammatory diseases; preclinical studies demonstrated immunomodulatory and anti-inflammatory effects in vitro and in vivo [S1].
• The company’s strategy includes advancing COYA 302 for ALS and FTD, developing COYA 303 for Alzheimer’s and other neurodegenerative diseases, establishing COYA 301 as a backbone for combination therapies, and pursuing partnerships and licensing opportunities [S1].
• Coya has entered into a Development and License Agreement with Dr. Reddy's Laboratories for COYA 302 commercialization in multiple territories, with milestone and royalty payments structured in the agreement [S1].
• The company has a Sponsored Research Agreement with Houston Methodist Research Institute supporting exosome research and other collaborations [S1].
• Financially, for the year ended December 31, 2025, Coya reported revenue of $7.95 million, a net loss of $21.2 million, and basic and diluted EPS of -$1.27 [S1].
• As of December 31, 2025, cash and cash equivalents were $46.8 million, current assets $49.9 million, current liabilities $5.87 million, with a current ratio of 8.5 and cash ratio of 7.97, indicating strong liquidity [S1].
• The company has incurred significant operating losses since inception and expects to continue incurring losses as it advances clinical development and prepares for potential commercialization [S1].
• Recent analyst coverage includes multiple buy recommendations from D. Boral Capital, Chardan Capital, and BTIG throughout late 2025, reflecting positive market interest [N1,N2,N3,N4,N5,N6,N7].